Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 3 | 2024 | 216 | 1.980 |
Why?
|
| Bile Duct Neoplasms | 3 | 2025 | 54 | 1.250 |
Why?
|
| Klatskin Tumor | 1 | 2024 | 1 | 0.890 |
Why?
|
| Waiting Lists | 1 | 2024 | 52 | 0.860 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 90 | 0.850 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 112 | 0.820 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 33 | 0.700 |
Why?
|
| Hydronephrosis | 1 | 2020 | 8 | 0.660 |
Why?
|
| Kidney Pelvis | 1 | 2020 | 13 | 0.660 |
Why?
|
| Ureteral Obstruction | 1 | 2020 | 25 | 0.650 |
Why?
|
| Cysts | 1 | 2020 | 41 | 0.650 |
Why?
|
| Ureter | 1 | 2020 | 37 | 0.640 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 276 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 341 | 0.560 |
Why?
|
| Gout Suppressants | 1 | 2015 | 22 | 0.460 |
Why?
|
| Gout | 1 | 2015 | 48 | 0.450 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1311 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2015 | 204 | 0.410 |
Why?
|
| Transplant Recipients | 2 | 2022 | 35 | 0.370 |
Why?
|
| Neoplasms | 1 | 2022 | 1364 | 0.360 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2021 | 13 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 178 | 0.280 |
Why?
|
| Incidence | 2 | 2022 | 1380 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 297 | 0.260 |
Why?
|
| Biliary Tract Diseases | 1 | 2025 | 22 | 0.230 |
Why?
|
| Endoscopy, Digestive System | 1 | 2025 | 33 | 0.230 |
Why?
|
| Cholestasis | 1 | 2025 | 65 | 0.230 |
Why?
|
| Male | 7 | 2025 | 29927 | 0.200 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 179 | 0.190 |
Why?
|
| Presenilin-1 | 2 | 2012 | 61 | 0.190 |
Why?
|
| Survival Rate | 1 | 2024 | 851 | 0.190 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6670 | 0.180 |
Why?
|
| Risk Factors | 2 | 2022 | 5359 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 31 | 0.180 |
Why?
|
| SEER Program | 1 | 2021 | 74 | 0.180 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 22 | 0.170 |
Why?
|
| Humans | 11 | 2025 | 63512 | 0.160 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2019 | 4 | 0.160 |
Why?
|
| bcl-X Protein | 1 | 2019 | 21 | 0.160 |
Why?
|
| Middle Aged | 5 | 2025 | 17641 | 0.160 |
Why?
|
| Nephrectomy | 1 | 2020 | 91 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 154 | 0.150 |
Why?
|
| Aged | 3 | 2025 | 14469 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 322 | 0.140 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 8 | 0.140 |
Why?
|
| Age Factors | 1 | 2021 | 1561 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2018 | 207 | 0.130 |
Why?
|
| Time Factors | 1 | 2024 | 3770 | 0.130 |
Why?
|
| Female | 6 | 2025 | 32912 | 0.120 |
Why?
|
| Alzheimer Disease | 2 | 2012 | 721 | 0.120 |
Why?
|
| Adult | 3 | 2021 | 16837 | 0.110 |
Why?
|
| Apoptosis | 1 | 2019 | 1079 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2021 | 2082 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 2 | 2012 | 297 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 232 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1647 | 0.090 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 86 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2015 | 753 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2019 | 1513 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 444 | 0.080 |
Why?
|
| Neurons | 2 | 2012 | 923 | 0.080 |
Why?
|
| Aging | 1 | 2012 | 745 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2025 | 129 | 0.060 |
Why?
|
| Biopsy | 1 | 2025 | 444 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 897 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1277 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2019 | 110 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2019 | 218 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2017 | 4 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2017 | 17 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 10846 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2017 | 33 | 0.030 |
Why?
|
| Rituximab | 1 | 2017 | 88 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 47 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 584 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 624 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2017 | 127 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 855 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 980 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 20666 | 0.020 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2012 | 20 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2012 | 40 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 59 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 127 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 612 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 401 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 298 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 410 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 780 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2157 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7855 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 5471 | 0.010 |
Why?
|